RA
PGNX

Royce & Associates’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Royce & Associates’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-974,439
Closed -$4.93M – 1205
2019
Q3 		$4.93M Hold
974,439
– – 0.05% 482
2019
Q2 		$6.01M Sell
974,439
-227,200
-19% -$1.1M 0.05% 449
2019
Q1 		$5.58M Sell
1,201,639
-195,000
-14% -$882K 0.05% 483
2018
Q4 		$5.87M Sell
1,396,639
-56,817
-4% -$289K 0.05% 463
2018
Q3 		$9.11M Buy
1,453,456
+276,200
+23% +$2.12M 0.06% 433
2018
Q2 		$9.46M Buy
1,177,256
+15,000
+1% +$115K 0.07% 409
2018
Q1 		$8.67M Sell
1,162,256
-48,600
-4% -$323K 0.06% 420
2017
Q4 		$7.21M Sell
1,210,856
-73,918
-6% -$449K 0.05% 490
2017
Q3 		$9.46M Sell
1,284,774
-61,600
-5% -$391K 0.06% 401
2017
Q2 		$9.14M Buy
1,346,374
+95,700
+8% +$706K 0.06% 419
2017
Q1 		$11.8M Sell
1,250,674
-208,500
-14% -$2.08M 0.08% 347
2016
Q4 		$12.6M Sell
1,459,174
-269,176
-16% -$1.99M 0.08% 321
2016
Q3 		$10.9M Sell
1,728,350
-185,000
-10% -$1.12M 0.07% 353
2016
Q2 		$8.07M Sell
1,913,350
-225,000
-11% -$1.09M 0.05% 449
2016
Q1 		$9.32M Sell
2,138,350
-143,900
-6% -$641K 0.06% 411
2015
Q4 		$14M Sell
2,282,250
-696,700
-23% -$4.57M 0.08% 317
2015
Q3 		$17M Sell
2,978,950
-242,900
-8% -$1.86M 0.09% 274
2015
Q2 		$24M Buy
3,221,850
+1,514,000
+89% +$9.16M 0.1% 258
2015
Q1 		$10.2M Buy
1,707,850
+25,000
+1% +$157K 0.04% 565
2014
Q4 		$12.7M Buy
1,682,850
+1,002,850
+147% +$6M 0.04% 520
2014
Q3 		$3.53M Buy
+680,000
New +$3.39M 0.01% 882

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Royce & Associates's PGNX Position: Q4 2019 in Review

Royce & Associates sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2019, closing a stake of 974,439 shares — an estimated $4.93M sold.

Royce & Associates first reported a position in PGNX in Q3 2014 and held it in 21 quarters. The position peaked at $24M in Q2 2015. 128 funds tracked by Wall St. Rank hold PGNX as of Q4 2019.

  • Royce & Associates reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2019 after selling out during the quarter.
  • Royce & Associates sold 974,439 Progenics Pharmaceuticals Inc shares in Q4 2019, an estimated $4.93M.
  • Royce & Associates first reported a position in Progenics Pharmaceuticals Inc in Q3 2014 and held it in 21 quarters.
  • Royce & Associates's Progenics Pharmaceuticals Inc position peaked at $24M in Q2 2015.
  • 128 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2019.

Based on Royce & Associates's 13F filing for Q4 2019, filed 6 Feb 2020.